Overview of BB Use and Outcomes in HFmrEF and HFpEF

Author(s):

Javed Butler, MD, MPH, MBA, discusses the data from European Society of Cardiology Congress 2024 on β-blocker use in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, focusing on the study’s objective, design, and methodology as well as key results and takeaways regarding the role of β-blockers in the multimodal management of these HF types.

EP: 1.Overview of FINEARTS-HF Trial

EP: 2.Role of MRAs in HFmrEF and HFpEF

Now Viewing

EP: 3.Overview of BB Use and Outcomes in HFmrEF and HFpEF

EP: 4.Multi-Modal Treatment Strategy for HFmrEF and HFpEF

EP: 5.Unmet Needs in the HFmrEF and HFpEF Landscape

EP: 6.Overview of DAPA ECHO Trial

Video content above is prompted by the following:

Discuss the data presented at European Society of Cardiology Congress 2024 on β-blocker (βB) use and outcomes in patients with heart failure with midrange ejection fraction (HFmrEF) and HF with preserved EF (HFpEF).
What was the objective of this analysis?
How was this study designed, and what methodology was used?
What results were presented?
Provide your key takeaways from this study. How do βBs play into the multimodal management of HFmrEF and HFpEF?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!